About
MSAT/ Process Development scientist with 4 years of immersive, hands-on industry…
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Publications
-
Concurrent chemotherapy and temozolomide-resistant CAR-T immunotherapy enhances glioblastoma clearance in experimental animals
Cancer Research
-
Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells
Cancer letters
-
IMMU-39. FIRST-IN-KIND T CELLS CARRYING A CHIMERIC ANTIGEN RECEPTOR AGAINST AN EXTRACELLULAR MATRIX PROTEIN TARGET GLIOBLASTOMA CELLS AND SHOW ANTI-TUMOR EFFICACY
Neuro-oncology
-
TARGETING GLIOMA STEM CELLS WITH CAR-T IMMUNOTHERAPY IN XENOGRAFT ANIMAL MODELS
Neuro-oncology
-
Immu-01. Temozolomide-resistant Car-t Enhances Glioblastoma Clearance By Concurrent Chemotherapy And Immunotherapy
Neuro-oncology
-
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells
Science Translational Medicine
Languages
-
English
Native or bilingual proficiency
-
Hindi
Native or bilingual proficiency
-
Bengali
Native or bilingual proficiency
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Sudarshana Sengupta
-
Sudarshana Sengupta
Editor | Special Projects & Brand Innovations | The Quint
-
Sudarshana Sengupta
GM - Sales & Marketing
-
SUDARSHANA SENGUPTA
Squadron Leader (Retd.) at Indian Air Force
-
Sudarshana Sengupta
Application Manager-at Alere Medical India Pvt Ltd
7 others named Sudarshana Sengupta are on LinkedIn
See others named Sudarshana Sengupta